Role of Posaconazole Drug in the Treatment of Invasive Fungal Disease: A Review

Overview

Journal Infect Disord Drug Targets

Publisher Bentham Science Publishers

Specialty Infectious Diseases

Date 2024 Sep 24

PMID 39313878

Authors

Sushil Kumar Singh

Shyam Sundar Pancholi

Affiliations

Soon will be listed here.

Abstract

Posaconazole is an antifungal medication used primarily to treat invasive fungal infections caused by various organisms, such as Aspergillus, Candida, and certain molds. It belongs to the class of drugs known as triazole antifungals. Clinical studies have reported posaconazole to be effective in treating various invasive fungal infections, especially in patients who are immunocompromised, such as those with weakened immune systems due to conditions like HIV/AIDS, undergoing chemotherapy, or having received an organ transplant. It has effectively treated invasive candidiasis, aspergillosis, zygomycosis, and other serious fungal infections. The effectiveness of the drug varies based on factors, such as the type of infection, the patient's immune status, and the site of infection. This review describes the types of infection, the drug's safety profile, the development of resistance to posaconazole, and strategies to manage or prevent resistance.

References

Bongomin F, Ekeng B, Kibone W, Nsenga L, Olum R, Itam-Eyo A . Invasive Fungal Diseases in Africa: A Critical Literature Review. J Fungi (Basel). 2022; 8(12). PMC: 9853333. DOI: 10.3390/jof8121236. View

Jorda T, Puig S . Regulation of Ergosterol Biosynthesis in . Genes (Basel). 2020; 11(7). PMC: 7397035. DOI: 10.3390/genes11070795. View

Maertens J, Rahav G, Lee D, Ponce-de-Leon A, Ramirez Sanchez I, Klimko N . Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial. Lancet. 2021; 397(10273):499-509. DOI: 10.1016/S0140-6736(21)00219-1. View

Chen X, Wang J, Wang S, Jin J, Li J, Gao S . Real-world assessment of the effectiveness of posaconazole for the prophylaxis and treatment of invasive fungal infections in hematological patients: A retrospective observational study. Medicine (Baltimore). 2021; 100(30):e26772. PMC: 8322488. DOI: 10.1097/MD.0000000000026772. View

Abuhelwa A, Williams D, Upton R, Foster D . Food, gastrointestinal pH, and models of oral drug absorption. Eur J Pharm Biopharm. 2016; 112:234-248. DOI: 10.1016/j.ejpb.2016.11.034. View

Scott I, Hilmer S, Reeve E, Potter K, Le Couteur D, Rigby D . Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med. 2015; 175(5):827-34. DOI: 10.1001/jamainternmed.2015.0324. View

Muller C, Neugebauer T, Zill P, Lass-Florl C, Bracher F, Binder U . Sterol Composition of Clinically Relevant Mucorales and Changes Resulting from Posaconazole Treatment. Molecules. 2018; 23(5). PMC: 6100088. DOI: 10.3390/molecules23051218. View

Jacquier N, Schneiter R . Mechanisms of sterol uptake and transport in yeast. J Steroid Biochem Mol Biol. 2010; 129(1-2):70-8. DOI: 10.1016/j.jsbmb.2010.11.014. View

Ke C, Deng F, Chuang C, Lin C . Antimicrobial Actions and Applications of Chitosan. Polymers (Basel). 2021; 13(6). PMC: 7998239. DOI: 10.3390/polym13060904. View

10.

Karaburun A, Kaya Cavusoglu B, Acar Cevik U, Osmaniye D, Saglik B, Levent S . Synthesis and Antifungal Potential of Some Novel Benzimidazole-1,3,4-Oxadiazole Compounds. Molecules. 2019; 24(1). PMC: 6337182. DOI: 10.3390/molecules24010191. View

11.

Morris M . Posaconazole: a new oral antifungal agent with an expanded spectrum of activity. Am J Health Syst Pharm. 2009; 66(3):225-36. DOI: 10.2146/ajhp070532. View

12.

Cortes J, Curto M, Carvalho V, Perez P, Ribas J . The fungal cell wall as a target for the development of new antifungal therapies. Biotechnol Adv. 2019; 37(6):107352. DOI: 10.1016/j.biotechadv.2019.02.008. View

13.

Hamperl S, Cimprich K . Conflict Resolution in the Genome: How Transcription and Replication Make It Work. Cell. 2016; 167(6):1455-1467. PMC: 5141617. DOI: 10.1016/j.cell.2016.09.053. View

14.

Riquelme M, Aguirre J, Bartnicki-Garcia S, Braus G, Feldbrugge M, Fleig U . Fungal Morphogenesis, from the Polarized Growth of Hyphae to Complex Reproduction and Infection Structures. Microbiol Mol Biol Rev. 2018; 82(2). PMC: 5968459. DOI: 10.1128/MMBR.00068-17. View

15.

Guntuku L, Naidu V, Yerra V . Mitochondrial Dysfunction in Gliomas: Pharmacotherapeutic Potential of Natural Compounds. Curr Neuropharmacol. 2016; 14(6):567-83. PMC: 4981742. DOI: 10.2174/1570159x14666160121115641. View

16.

Ibe C, Munro C . Fungal Cell Wall Proteins and Signaling Pathways Form a Cytoprotective Network to Combat Stresses. J Fungi (Basel). 2021; 7(9). PMC: 8466366. DOI: 10.3390/jof7090739. View

17.

Li J, Nguyen C, Garcia-Diaz J . Role of New Antifungal Agents in the Treatment of Invasive Fungal Infections in Transplant Recipients: Isavuconazole and New Posaconazole Formulations. J Fungi (Basel). 2018; 1(3):345-366. PMC: 5753129. DOI: 10.3390/jof1030345. View

18.

Soysal A . Prevention of invasive fungal infections in immunocompromised patients: the role of delayed-release posaconazole. Infect Drug Resist. 2015; 8:321-31. PMC: 4573198. DOI: 10.2147/IDR.S65592. View

19.

Auberger J, Lass-Florl C, Aigner M, Clausen J, Gastl G, Nachbaur D . Invasive fungal breakthrough infections, fungal colonization and emergence of resistant strains in high-risk patients receiving antifungal prophylaxis with posaconazole: real-life data from a single-centre institutional retrospective observational.... J Antimicrob Chemother. 2012; 67(9):2268-73. DOI: 10.1093/jac/dks189. View

20.

Wong T, Loo Y, Veettil S, Wong P, Divya G, Ching S . Efficacy and safety of posaconazole for the prevention of invasive fungal infections in immunocompromised patients: a systematic review with meta-analysis and trial sequential analysis. Sci Rep. 2020; 10(1):14575. PMC: 7471265. DOI: 10.1038/s41598-020-71571-0. View